S3 Ep38: Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.
35m Sep 14, 2020
35m
S3 Ep37: Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
In our exclusive interview, Sara M. Tolaney, MD, MPH, shared insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.
16m Sep 10, 2020
16m
S3 Ep36: Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
In our exclusive interview, Dr. Herzog and Dr. Moore reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.
30m Sep 07, 2020
30m
S3 Ep35: Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
In our exclusive interview, Dr. Coleman and Dr. Slomovitz discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
28m Sep 03, 2020
28m
S3 Ep34: GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.
27m Aug 31, 2020
27m
S3 Ep33: FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma
In our exclusive interview, Shilpa Gupta, MD, of Cleveland Clinic, discusses the FDA approval of avelumab in metastatic urothelial carcinoma and key findings from the JAVELIN Bladder 100 study.
12m Aug 27, 2020
12m
S3 Ep32: Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.
25m Aug 24, 2020
25m
S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.
12m Aug 20, 2020
12m
S3 Ep30: Pegram Unpacks Pivotal Data in Breast Cancer
In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, and potential adverse effects and recommended management strategies for the agent.
20m Aug 17, 2020
20m
S3 Ep29: Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma
In our exclusive interview, Marc J. Braunstein, MD, PhD, provided perspective on data in the up-front and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.
39m Aug 13, 2020
39m
S3 Ep28: Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.
19m Aug 10, 2020
19m
S3 Ep27: Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
In our exclusive interview, Don. S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.
21m Aug 06, 2020
21m
S3 Ep26: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
In an interview with OncLive, Dr. Wang discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.
15m Aug 03, 2020
15m
S3 Ep25: DiNardo Discusses VIALE-A and Venetoclax Combo in AML
In our exclusive interview, Dr. DiNardo discussed the role of venetoclax in AML and explained the significance of the results of the VIALE-A trial.
11m Jul 30, 2020
11m
S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
In our exclusive interview, Dr. Riess discussed the excitement surrounding KRAS G12C inhibitors in NSCLC, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.
11m Jul 27, 2020
11m
S3 Ep23: Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant non–small cell lung cancer.
26m Jul 23, 2020
26m
S3 Ep22: FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers
In our exclusive interview, Dr. Drilon provided background on use of targeted therapy in advanced NSCLC, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.
12m Jul 20, 2020
12m
S3 Ep21: Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos
In our exclusive interview, Dr. Sen and Dr. Groisberg highlight research evaluating checkpoint inhibitors and combination chemotherapy regimens in the evolving sarcoma treatment paradigm.
49m Jul 16, 2020
49m
S3 Ep20: First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma
In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.
33m Jul 13, 2020
33m
S3 Ep19: Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer
In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.
40m Jul 09, 2020
40m
S3 Ep18: FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC
In our exclusive interview, Edgardo S. Santos, MD, discusses the data that led to the approval of ramucirumab in combination with erlotinib and shares his thoughts on its utility in the frontline setting.
18m Jul 06, 2020
18m
S3 Ep17: Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon
In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.
12m Jul 02, 2020
12m
S3 Ep16: Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
In our exclusive interview, Dr. Weinberg, shares the clinical implications of these data in the treatment of patients with CRC and projected what the future may hold in the space.
28m Jun 29, 2020
28m
S3 Ep15: FDA Approval Insights: Olaparib in HRR-Mutant mCRPC
In our exclusive interview, Agarwal, who was also a member of the PROfound trial Global Steering Committee, discussed the approval of olaparib in HRR-mutant mCRPC, key efficacy and safety data from the PROfound trial, the importance of genomic sequencing in the metastatic setting, and ongoing research with PARP inhibitors in earlier lines of therapy.
24m Jun 25, 2020
24m
S3 Ep14: Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer
In our exclusive interview, Dr. Vokes discussed the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.
22m Jun 22, 2020
22m
S3 Ep13: Integrating Nutrition Into the Continuum of Cancer Care
In our exclusive interview, Dr. Hegazi, medical director of Adult Nutrition at Abbott, shed light on nutrition-related issues among patients with cancer, early intervention strategies for patients who experience loss of muscle mass and function, and the use of specialized nutrients to prevent muscle degradation.
24m Jun 18, 2020
24m
S3 Ep12: FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC
In our exclusive interview, Dr. Ramalingam, who is also a professor in the Department of Hematology and Medical Oncology and the Roberto C. Goizueta Distinguished Chair for Cancer Research at Emory University School of Medicine, shed light on key findings from the CheckMate-227 trial. He also discussed the impact of the approval on other frontline treatment regimens in the metastatic setting an...
11m Jun 15, 2020
11m
S3 Ep11: Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
In our exclusive interview, Dr. Gradishar shared the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.
16m Jun 11, 2020
16m
S3 Ep10: Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
In our exclusive interview, Dr. Hamid, director of the Melanoma Center and Phase I Immuno-Oncology Program and chief of Immunotherapy and Translational Research at The Angeles Clinic and Research Institute, highlighted key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma a...
14m Jun 08, 2020
14m
S3 Ep9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.
32m Jun 04, 2020
32m
S3 Ep8: Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era
In our exclusive interview, Dr. Chowdhary, a chief resident physician of Radiation Oncology at Rush University Medical Center, shared advice for family members living with patients with cancer, projected the long-term implications of the COVID-19 pandemic on clinical practice, provided insight on the effects of investigational treatments for patients with COVID-19, and detailed the protocols Ru...
22m Jun 01, 2020
22m
S3 Ep7: Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
In our exclusive interview, Beth Y. Karlan, of UCLA David Geffen School of Medicine, shared the rewarding moments as well as challenges navigating the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.
35m May 28, 2020
35m
S3 Ep6: Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
In our exclusive interview, Dr. Burris and Dr. Graff discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.
28m May 25, 2020
28m
S3 Ep5: FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma
We had the pleasure of speaking with Maria-Victoria Mateos, MD, PhD, to discuss the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.
19m May 21, 2020
19m
S3 Ep4: McGregor Details GU Treatment Guidelines During COVID-19 Pandemic
In our exclusive interview, Dr. McGregor discussed the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.
19m May 18, 2020
19m
S3 Ep3: FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer
In our exclusive interview, Dr. Herzog discusses the FDA approval of the combination of olaparib and bevacizumab as frontline maintenance therapy for patients with advanced ovarian cancer, the safety profile of the combination, and the clinical implications of the approval.
18m May 14, 2020
18m
S3 Ep2: Talking Tumors: Exploring Management Strategies in Multiple Myeloma
This week, we spoke with Nina Shah, MD and Sandy Wong, MD, both of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, to discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.
30m May 11, 2020
30m
S3 Ep1: Making Headway in GI Malignancies in Miami
We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies. At the meeting, faculty from the Florida Society of Clinical Oncology discussed the novel agents that are generating excitement in advanced hepatocellular carcinoma and cholangiocarcinoma and the novel therapies and strategies that are propelling progress in gastric cancer. Moreover, pane...
27m May 07, 2020
27m
S2 Ep50: The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers
We had the pleasure of sitting down with members of Uromigos, a group of genitourinary cancer oncologists from all over the world who share their oncologic insights through their collaborative Twitter account and in the form of their own podcasts. In an effort to share some of the evolving knowledge about COVID-19 pandemic and how it is impacting the healthcare system on a global scale, the ...
25m May 04, 2020
25m
S2 Ep49: Marvels in Medicine: Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer
In our exclusive interview, Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way and what he hopes to tackle in the rest of his monumental career.
39m Apr 30, 2020
39m
S2 Ep48: FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
In our exclusive interview, Aditya Bardia, MD, of Massachusetts General Hospital Cancer Center, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer, the implications of the approval, and ongoing research with the agent.
13m Apr 27, 2020
13m
S2 Ep47: Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio
We recently traveled to Columbus, Ohio for a State of the Science Summit on Ovarian Cancer. At the meeting, faculty from The Ohio University Comprehensive Cancer Center–James, discussed the importance of performing genetic testing upon diagnosis, shared insight on the evolution of ovarian cancer therapeutics, and provided perspective on individualized approaches in the frontline setting. Addit...
38m Apr 23, 2020
38m
S2 Ep46: Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer
We recently traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer. Jyoti D. Patel, MD, and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.
38m Apr 20, 2020
38m
S2 Ep45: Navigating Newfound GU Treatment Considerations in the Context of COVID-19
We had the pleasure of sitting down with Guru P. Sonpavde, MD, the director of the Bladder Cancer Program and a physician at Dana-Farber Cancer Institute. In our exclusive interview, Dr. Sonpavde discusses how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, specifically, as they relate to the dosing and scheduling of chemotherapy, immunotherapy, and tar...
19m Apr 16, 2020
19m
S2 Ep44: Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia
In this special edition of OncLive On Air, we collaborated with one of our sister brands, CURE, for an exclusive interview with Ruben Mesa, MD and his patient, Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, to discuss Hjerpe's treatment course, the current state of treatment in ET and ongoing research efforts, and resources to educate physicians and patients on M...
29m Apr 13, 2020
29m
S2 Ep43: Homing in on Clinical Advances in Hematologic Malignancies in Chicago
We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Rush University Medical Center shed light on ongoing research that is poised to add new options to the armamentarium in myelofibrosis, highlighted the novel agents that have strengthened treatment options in non-Hodgkin lymphoma, and discussed treatment consider...
28m Apr 09, 2020
28m
S2 Ep42: Gaining Ground in Genitourinary Malignancies in Nashville
We recently traveled to Nashville, Tennessee for a State of the Science Summit™ on Genitourinary Malignancies. At the meeting, faculty from Vanderbilt-Ingram Cancer Center shared insight on recent developments in prostate cancer. Specifically, panelists discussed selection criteria for androgen receptor-directed agents in nonmetastatic castration-resistant prostate cancer and explained how a po...
30m Apr 06, 2020
30m
S2 Ep41: Talking HER2-Targeted Therapy With Dr. Ajani
We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies. Listen on to hear Ajani discuss some of the HER2-targeted strategies that are under exploration in gastric/GEJ cancer and colorectal...
18m Apr 03, 2020
18m
S2 Ep40: Talking HER2-Targeted Therapy With Dr. Chau
We had the pleasure of speaking with Ian Chau, MD, FRCP, who discussed the state of HER2-directed therapy in gastric/gastroesophageal cancer. Listen on to hear Chau discuss HER2 testing in gastric/GEJ cancer and several HER2-targeted strategies under evaluation.
15m Apr 03, 2020
15m
S2 Ep39: Talking HER2-Targeted Therapy With Dr. Marshall
We had the pleasure of speaking with John L. Marshall, MD, who discussed the evolving treatment landscape of HER2-targeted treatment strategies in colorectal cancer. Listen on to hear Marshall discuss the necessity of identifying patients with HER2-positive colorectal cancer and the work being done to better elucidate effective targeted treatments for patients.
10m Apr 03, 2020
10m